Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

Am J Hum Genet. 1997 Feb;60(2):265-71.
No abstract available

Publication types

  • Editorial
  • Research Support, U.S. Gov't, P.H.S.
  • Review
  • Comment

MeSH terms

  • Acetylation
  • Animals
  • Arylamine N-Acetyltransferase / genetics*
  • Arylamine N-Acetyltransferase / metabolism
  • Bioethics
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 CYP2D6 / metabolism
  • Debrisoquin / metabolism
  • Diet
  • Disease Susceptibility
  • Ethnicity
  • Glucosephosphate Dehydrogenase / genetics*
  • Glucosephosphate Dehydrogenase / metabolism
  • Humans
  • Neoplasms / genetics
  • Oxidation-Reduction
  • Polymorphism, Genetic*

Substances

  • Glucosephosphate Dehydrogenase
  • Cytochrome P-450 CYP2D6
  • Arylamine N-Acetyltransferase
  • Debrisoquin